#$%^&*AU2018200108A120180125.pdf#####ABSTRACT OF THE DISCLOSURE The present disclosure relates to methods for weight management in an individual in need thereof by 5 determining the level of renal sufficiency of the individual and prescribing or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual, provided that the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment. In addition, the disclosure relates to a method 10 for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management by determining the level of renal sufficiency of the individual and selecting the individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual 15 has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment.1/14 CL 01 0. 2 Z a7e C-I* 00 c~co +1 (Iwi510uo U0WLOzDUOD ewseld ~a)
